HostColor Kicks Off Go Serverless WordPress Cloud and Metal Servers
HostColor.com (HC) is pleased to announce the launch of two new Function-as-a-Service (FaaS)-based application hosting infrastructure service plans: "Go Serverless Cloud" and "Go Serverless Metal."
Serverless WordPress Hosting Infrastructure
New York, New York, May 13, 2025 (GLOBE NEWSWIRE) -- HostColor.com (HC), a globally recognized cloud infrastructure and managed server provider (MSP), announced the immediate availability of Function-as-a-Service (FaaS) based serverless WordPress hosting infrastructure with two customizable service plans - "Go Serverless WordPress Cloud" and "Go Serverless WordPress Metal".
Go Serverless WordPress Cloud
"Go Serverless WordPress Cloud" includes: WordPress is a Dedicated Cloud Hosting environment; Caching for a super-fast WordPress site; Threat detection and blocking; Daily backups (on demand), Regular WP version updates; Regular WP plugin updates; Maintenance of a WordPress-based e-commerce store; 24/7 live support; Technical administration of WP-related applications; Scalable unmetered bandwidth; Scalable SSD storage (sirtual disk); OS management & security hardening; Dedicated IP address; Uptime monitoring; SEO-optimized WordPress installation.
The entry-level Go Serverless WordPress Cloud plan includes 1 CPU core, 2 GB RAM, and 20 GB SSD or NMVe storage, which can be scaled on-demand at any time. The standard network service for the Serverless WordPress Cloud in HostCollor's Dallas data center includes 100 Mbps of unmetered bandwidth quota that can be scaled up to 1 Gbps. In other datacenter locations, the network service can be delivered as both a metered data transfer in terabytes (TB) per month on a 100 Mbps port speed, as well as an unmetered 1 Gbps port speed. All Go Serverless WordPress Cloud plans with 4 or more CPU cores come with unlimited data transfer up to the capacity of the bandwidth port, which varies in speed from 300 Mbps to 1000 Mbps.
Go Serverless WordPress Metal
"Go Serverless WordPress Metal" is an Unlimited Dedicated Hosting service in terms of the Internet traffic usage. It includes: WordPress hosted on a dedicated bare-metal environment; Caching for a super-fast WordPress site; Threat detection and blocking; Daily backups; Regular WP version updates; Regular WP plugin updates; Maintenance of a WordPress-based e-commerce store; 24/7 live support; Technical administration of WP-related applications; 250+ Mbps unmetered bandwidth; Large fixed dedicated SSD storage quota (physical disks); OS management & security hardening; Dedicated IP address; Uptime monitoring; SEO-optimized WordPress. "Unlimited Dedicated Hosting" means that users of the Go Serverless WordPress Metal service are entitled to unlimited data transfer up to the physical capacity of the Internet connection port. The most important feature of the "unlimited" Internet traffic feature is that WordPress Metal users are not charged any data transfer fees.
Go Serverless WordPress Metal plans include dedicated CPU, RAM, and storage resources. They start with 4 CPU cores and 16 GB RAM with 480 GB SSD and can scale up to more than 40 CPU cores, more than 1024 GB RAM and terabytes of SSD or NMVe storage, depending on availability.
HC's Go Serverless WordPress Metal customers enjoy unlimited data transfer up to the logical or physical capacity of the Internet connection port and never pay for excess data transfer per gigabyte (GB) or terabyte (TB).
Users of the Go Serverless WordPress Cloud and Serverless WordPress Metal FaaS plans can choose any Linux operating system (OS), with Ubuntu versions 20, 22, 24, Rocky Linux versions 8 and 9, AlmaLinux versions 8 and 9, and Debian versions 10, 11, and 12 available for out-of-the-box deployment. Selected Microsoft Windows operating systems (OS) are also available upon request.
Serverless WordPress Metal FaaS infrastructure plans can be deployed with the user's preferred virtualization platform, including Proxmox VE, VMware ESXi, Linux Containers, VirtualBox, OpenVZ, Kubernetes, Docker, or any other virtualization platform. Proxmox VE versions 6, 7, and 8 are HostColor's preferred platform for enterprise cloud automation.
HostColor has recently announced new offerings for high-bandwidth and high-performance AMD dedicated servers. They are available for immediate deployment in Ashburn, Chicago, Dallas, Denver, Detroit, Los Angeles, New York, Phoenix, and Seattle in the United States, Montreal and Toronto in Canada, and Frankfurt, Madrid, and Zurich in Germany, Spain, and Switzerland.
About HostColor
Since 2000, HostColor.com (HC) has been a global provider of semi-managed edge, bare metal, and cloud infrastructure and IT hosting services. The company operates virtual data centers and provides dedicated hosting and colocation services from over 100 data centers worldwide, with its subsidiary, HostColorEurope.com, providing cloud infrastructure and dedicated hosting services in 19 European countries. For more information, visit https://www.hostcolor.com.
Media Contact
PR Department
+1 888-222-1495
pr@hostcolor.com
Attachment
Serverless WordPress Hosting Infrastructure
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Hi-View Clarifies Non-Brokered Private Placement
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- HI-VIEW RESOURCES INC. ('HI-VIEW' OR THE 'COMPANY') (CSE: HVW; OTCQB: HVWRF; FSE: B63) Further to the Company's news release issued on May 28, 2025 announcing the non-brokered private placement, the Company further clarifies that the Company will rely on the exemption set out in Section 4.6(2)(b) of CSE Policy 4 - Corporate Governance, Security Holder Approvals and Miscellaneous Provisions (the "Policy") with respect to the requirement to obtain shareholder approval of such transaction whereby the Company is issuing more than 100% of its issued share capital on a fully diluted basis (relating to the Private Placement warrants). The Company applied and was granted by the CSE the exemption from shareholder approval based on the following: The Company is in financial hardship, has reached an agreement to complete the offering, no related persons as defined in Policy 1 will participate in the transaction; and has been approved by the majority of the independent directors of the Company. The non-brokered private placement will consist of up to 4,800,000 units (each a 'Unit') at a price of $0.10 per Unit for gross proceeds of up to $480,000 (the 'Private Placement'). Each Unit will consist of one common share (each, a 'Share') and one transferrable common share purchase warrant (each, a 'Warrant'). Each Warrant entitles the holder to purchase one additional Share of the Company at a price of $0.12 per Share for a period of 36 months from the date of issuance. Following closing of the Private Placement there will be 9,640,060 shares outstanding on a non-diluted basis. The net proceeds from the Placement will be allocated towards general corporate purposes including arm's length payables, exploration activities on its Toodoggone Projects. In accordance with the regulations of the Canadian Securities Exchange ("CSE"), an up to 10% finder's fees may be applicable. All securities issued pursuant to the Private Placement will be subject to a hold period of four months and one day as required under applicable securities legislation. About Hi-View Resources Inc. Hi-View is a mineral exploration company focused on the acquisition, exploration and development of mineral properties in Canada. The Company, through its subsidiary, holds a 100% interest in the Babine BC Copper-Gold property as well as interests in the Golden Stranger Property and the Lawyers East, West, South and BEN claims, located in the prolific Toodoggone region of northern BC, highly prospective for gold, silver, and copper. The collective holdings cover over 9,749 hectares. On Behalf of the Board of Directors, 'R. Nick Horsley'R. Nick Horsley, CEO For further information, please contact: Hi-View Resources Milne - PresidentEmail: hdmcap@ Telephone: (604) 377-8994Website: FORWARD LOOKING STATEMENTS: This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking statements in this news release includes statements related to the proposed Transaction and related matters. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. 1,2 AuEq in Thesis News Release dated Spetember5th, 2024 is defined in the mineral resources as being Au=Ag/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Global Trading Card Game Authentication Services Market Size to Surpass US$ 6,611.93 Million By 2033
Fueled by escalating collector caution, rapid technology upgrades, and intensifying regulatory oversight, the 2024 trading card game authentication services market is transforming into infrastructure delivering faster, greener, blockchain-secured grading and diversified data-driven revenue streams. Chicago, June 05, 2025 (GLOBE NEWSWIRE) -- The global trading card game authentication services market was valued at US$ 2,239.04 million in 2024 and is expected to reach US$ 6,611.93 million by 2033, growing at a CAGR of 13.13% during the forecast period 2025–2033. The fever surrounding Pokémon's 151 set, Lorcana's successive sell-outs, and One Piece Card Game's headline launch have kept third-party graders busier than ever. PSA alone encapsulated 7.5 million TCG cards during 2023, a jump of 1.4 million units over the prior year. eBay reports 2.3 million authenticated singles shipped through its Authenticity Guarantee hub, underscoring a consumer base that refuses to trade raw cards after a $2.1 million fake Black Lotus ring was exposed in February 2024. Reinforced by such fraud busts, the trading card game authentication services market now sits at the heart of every serious transaction, while hobby shops redirect bulk submissions because slabbed inventory turns faster online. Download Sample Pages: Private-equity funds, notably the Altan-backed Collectible Opportunity Fund, treat graded TCG pieces as short-duration alternative investments and demand ISO 17025-calibrated graders. Fractional-ownership platforms such as Rally and Otis will no longer accept cards without verifiable serials that pass a public API check, a policy introduced after a surge in counterfeit MetaZoo items. Consequently, dealers across Singapore, Düsseldorf, and São Paulo are fast-tracking submittals to remain competitive, further accelerating activity within the trading card game authentication services market and binding its fortunes directly to both retail and institutional appetite. Key Findings in Global Trading Card Game Authentication Services Market Market Forecast (2033) US$ 6,611.93 million CAGR 13.13% Largest Region (2024) North America (40%) By Service Type Grading Services (62.71%) By Technology QR Code Scanning (35.54%) By Application Sport Cards (40.11%) By End Users Individual Collectors (42.44%) Top Drivers Post-pandemic collectible surge driving record grading submissions and authentication demand. High-value auction results incentivize collectors to seek professional provenance verification. AI-enhanced scanning improves throughput, reducing turnaround costs for grading firms. Top Trends Embedded NFC slabs enable instant mobile authentication, heightening consumer engagement. European satellite labs reduce cross-border shipping risk, bolstering regional grading. Partnerships with e-commerce platforms integrate grading status directly into listings. Top Challenges Counterfeits employing advanced printing techniques outpace traditional visual inspection protocols. Regional regulatory discrepancies complicate insurance valuation standards for authenticated cards. Rising labor costs strain mid-tier graders lacking substantial automation investments. Technology Innovations Revolutionize Card Authentication Accuracy and Processing Times Rapidly Machine-learning vision, ultraviolet fluorescence mapping, and 8-gigapixel stitching have collapsed PSA's average turnaround from 25 days in early 2023 to nine days by March 2024. Beckett's new VisionPRO rig now batch-scans 450 cards per hour, while SGC's LUCIA platform measures centering within 0.15 millimeters. Hardware gains dovetail with cloud-based model retraining, allowing algorithms to learn from every submission without manual tagging, thereby tightening grading consistency across offices. Precision upgrades reinforce confidence, not just speed. CGC maintains a 30-terabyte library that maps ink dispersion across 186 verified paper stocks, blocking high-quality proxies from Shenzhen print farms. Blockchain-anchored audit logs feed directly into marketplace APIs, enabling instant listing verification. As a result, the trading card game authentication services market is shifting from artisanal craftsmanship toward data-driven reproducibility. Consumers enjoy smoother cross-border deals, insurers gain hard defect probabilities, and overall trust elevates the trading card game authentication services market to infrastructure status. Competitive Landscape Expands As New Entrants Address Niche Collector Needs Brand reputation once formed the primary moat, yet 2024 is witnessing specialized graders move into underserved corners of the hobby. Osaka-based Cardriffic launched in January with bilingual support for Weiss Schwarz and Vanguard, logging 48,000 submissions in its first quarter. Madrid's Grade4Good courts eco-conscious fans by using recycled PETG slabs and water-borne inks, while partnering with DHL eCommerce to offer sub-$12 return shipping that legacy firms struggle to match. Incumbents are responding aggressively. In April 2024 PSA's parent, Collectors Holdings, invested in UK-based PeerPass, whose NFC chips slide between card and sleeve without adding thickness. Such add-ons defend market share even as venture capital pours in—Crunchbase lists 17 card-grading funding rounds since July 2023 totaling $98 million. Each infusion heightens service differentiation, spawning anime-themed labels and subscription-bundled population reports that keep the trading card game authentication services market vibrant. Ultimately, innovation pressure raises the performance bar across the market and expands choice for collectors. Regulatory Scrutiny and Intellectual Property Enforcement Shape Service Compliance Requirements Public agencies now view graded TCG assets as potential conduits for illicit finance. FinCEN's 2023 Notice on High-Value Collectibles added graded cards to its watchlist, forcing large submission centers to adopt customer-due-diligence protocols similar to bullion dealers. Germany's Zoll customs service pilots machine-vision kiosks at Frankfurt Airport to flag slabbed items with suspicious valuations after counterfeit Pikachu Illustrator seizures totaling €11.2 million. IP owners also act decisively. The Pokémon Company International filed a landmark suit in January 2024 against an Arizona seller whose falsely authenticated cards exploited holographic trademarks, citing 'willful negligence' by the grader. The language shook confidence across the trading card game authentication services market. Graders now maintain encrypted photo archives and tamper-evident sleeves applauded by EUIPO officials. Compliance costs rise, yet marketplace trust deepens—an equilibrium rapidly becoming a competitive moat within the evolving market. Regional Dynamics Highlight Asia-Pacific Surge and European Platform Consolidations Ahead Capacity has migrated east. PSA's Hong Kong hub processed 1.9 million TCG cards in 2023, eclipsing its California volume for the first time. Singapore's Qube Grading moved to a 24-hour roster to handle nightly air-cargo deliveries, while Tokyo retailer Hareruya 2 sold 11,400 graded One Piece singles during Golden Week alone. Bandai's dense event calendar and the rise of cashless high-street resellers amplify submission momentum. Europe tells a different story. French player PCA acquired Belgium's CardCase in February 2024, and rumors swirl of a Nordic buyout spree aiming to build a pan-EU logistics network. These tie-ups seek to offset post-Brexit customs delays that add six days to door-to-door times. Accordingly, the trading card game authentication services market exhibits divergent regional signatures: capacity expansion dominates Asia-Pacific, whereas consolidation efficiencies headline Europe. Still, both vectors focus on faster, safer slabs, anchoring long-term growth in the market. Digital Twins and Blockchain Underpin Next-Generation Provenance Verification Tools Today Digital twins now accompany slabs as JSON certificates on permissioned Polygon Supernets. CGC's November 2023 beta minted 210,000 tokenized reports, allowing vault-stored Grail pieces to trade ownership without physical movement. Twelve condition variables, from surface gloss to corner tensile strength, are hashed alongside graders' private signatures; repairs append rather than overwrite records, preserving immutable custody chains. Marketplaces reacted quickly. TCGplayer integrated wallet-less verification, cutting Pokémon return claims from 3,420 in Q4 2022 to 1,180 a year later. Lower indemnity reserves please insurers and raise trust during Whatnot livestreams. Because blockchain travels worldwide instantly, it internationalizes the trading card game authentication services market and frees liquidity once trapped by geography. As more graders commit to shared ledgers, composability becomes the next competitive frontier within the market. Need Custom Data? Let Us Know: Future Outlook Forecasts Diversified Revenue Streams Beyond Traditional Grading Services Graders are testing services that stretch beyond numeric scores. Beckett's October 2024 pilot offers real-time condition monitoring at $4.99 per slab per year for vault clients, while PSA's collaboration with Immutable provides 'Game-Ready' certification for cards eligible in officially sanctioned digital tournaments, blurring lines between physical and online play. These add-ons scale profitability without more plastic. Monetization is also shifting to data licensing. Population reports now feed anonymized trend analytics to hedge-fund dashboards and insurers at roughly $2 per graded card annually, elevating the trading card game authentication services market from back-end utility to real-time pricing oracle. Advisory layers—portfolio rebalancing guidance, estate planning, even AI-driven sell-through optimization—are appearing on PSA Japan's rate card. As such services mature, they promise to embed the market deeper into the value stack of collecting, investing, and competitive gameplay alike. Global Trading Card Game Authentication Services Market Key Players: PSA (Professional Sports Authenticator) CGC (Certified Guaranty Company) ARS SGC (Sportscard Guaranty Corporation) GetGraded MNT Grading ACE Grading Card Grading Australia TGA Other Prominent Players Key Segmentation: By Service Type Grading Services Manual Grading Fully Automated Grading Hybrid Grading Certification Services Encapsulation/Slabbing Appraisal Services Verification Services By Technology Blockchain Authentication QR Code Scanning AI and Machine Learning RFID/NFC By Application Collectible Cards Sports Cards Sealed Boxes and Packs Digital Trading Cards Rare or Limited-Edition Cards By End User Individual Collectors Resellers and Dealers Authentication Agents Card Shops and Retailers By Submission Channel Direct Submissions Retailer / Dealer Submissions International Agents By Region North America Europe Asia Pacific Middle East & Africa (MEA) South America Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
35 minutes ago
- Yahoo
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies
The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options. Additionally, greater awareness and screening initiatives are supporting earlier diagnosis and management. New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options. Additionally, greater awareness and screening initiatives are supporting earlier diagnosis and management. DelveInsight's Dilated Cardiomyopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging dilated cardiomyopathy drugs, market share of individual therapies, and current and forecasted dilated cardiomyopathy market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Dilated Cardiomyopathy Market Report According to DelveInsight's analysis, the total dilated cardiomyopathy market size in the 7MM was estimated to be nearly USD 464 million in 2023, and it is expected to grow positively by 2034. Amgen's CORLANOR (ivabradine) generated the second-highest revenue of USD 90.3 million in the US in 2023. In the 7MM, the total dilated cardiomyopathy prevalence was estimated to be approximately 3 million in 2023, of which the US accounted for around 45%. Prominent companies, including Bristol-Myers Squibb, Berlin Cures, Cumberland Pharmaceutical, Rocket Pharmaceutical, Solid Bioscience, and others, are actively working on innovative dilated cardiomyopathy drugs. These novel dilated cardiomyopathy therapies are anticipated to enter the dilated cardiomyopathy market in the forecast period and are expected to change the market. Some of the key dilated cardiomyopathy treatments include Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), REN-001, AVB-401, SGT-601, and others. Discover which new treatment for dilated cardiomyopathy is expected to grab the market share @ Dilated Cardiomyopathy Market Report Dilated Cardiomyopathy Overview Dilated cardiomyopathy is a chronic and progressive heart disorder marked by the enlargement of the left ventricle, which impairs the heart's ability to pump blood effectively and can result in heart failure. By definition, patients exhibit systolic dysfunction, though they may or may not show clear signs of heart failure. The clinical presentation can vary widely from no symptoms to advanced heart failure. Common symptoms include shortness of breath during exertion, fatigue, palpitations, general dyspnea, swelling in the limbs, and arrhythmias such as ventricular tachycardia and atrial fibrillation. While many cases are idiopathic, some result from external factors such as viral infections (e.g., myocarditis), exposure to toxins (like excessive alcohol or chemotherapy drugs), autoimmune conditions, or nutritional deficiencies. Approximately 50% of cases have a genetic or familial basis. Diagnosing dilated cardiomyopathy involves a structured process to detect abnormalities in heart structure and function and to exclude other possible causes of cardiac impairment. This typically includes a thorough clinical evaluation, imaging techniques, lab investigations, and genetic Cardiomyopathy Epidemiology Segmentation The dilated cardiomyopathy epidemiology section provides insights into the historical and current dilated cardiomyopathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The dilated cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Dilated Cardiomyopathy Total Diagnosed Prevalent Cases of Dilated Cardiomyopathy Gender-specific Cases of Dilated Cardiomyopathy Familial and Non-familial Cases of Dilated Cardiomyopathy Download the report to understand which factors are driving dilated cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Treatment Options Dilated Cardiomyopathy Treatment Market Currently, there is no cure for dilated cardiomyopathy, but various treatments are available to manage symptoms and reduce the risk of complications. The choice of treatment depends on the extent of the heart's dysfunction and the patient's specific symptoms. The primary goals of treating cardiomyopathy are to: Prevent the condition from worsening, Address and manage any underlying or contributing health issues, and Minimize complications, including the risk of sudden cardiac arrest (SCA), with the ultimate aim of helping patients maintain a normal quality of life. Pharmacological interventions commonly used include diuretics, inotropic agents, afterload reducers, beta-blockers, anticoagulants, and anti-arrhythmic drugs. Inotropic agents used in treatment include digoxin, dobutamine, dopamine, epinephrine, norepinephrine, vasopressin, and milrinone. Afterload-reducing drugs include ACE inhibitors such as captopril, enalapril, lisinopril, and fosinopril, as well as angiotensin receptor blockers (ARBs) like losartan. Milrinone is notable for its dual action as an inotropic agent and vasodilator. ACE inhibitors and ARBs have shown effectiveness in managing heart failure with reduced ejection fraction and are recommended for patients with DCM. Stronger anticoagulants, including warfarin, heparin, and enoxaparin, require careful dosage adjustments and regular blood monitoring. Amgen's CORLANOR (ivabradine), approved by the US FDA, is currently the only dilated cardiomyopathy treatment drug in its class in the U.S. It works by selectively inhibiting the If current in the sinoatrial node, thereby slowing heart rate without affecting myocardial contractility or ventricular repolarization. In April 2019, the FDA approved CORLANOR for treating stable, symptomatic heart failure due to DCM in pediatric patients aged 6 months to 18 years. Dilated cardiomyopathy is a progressive disorder marked by continual myocardial injury, structural changes, and declining cardiac function. Hence, there is an urgent need for new treatments for dilated cardiomyopathy that can halt or delay disease progression, prevent adverse cardiac remodeling, and preserve heart function over time. Learn more about the dilated cardiomyopathy treatment options @ Dilated Cardiomyopathy Treatment Guidelines Dilated Cardiomyopathy Emerging Drugs and Companies Several novel therapies are under development, including Bristol-Myers Squibb's Danicamtiv (MYK-491), Berlin Cures' BC007, Cumberland Pharmaceuticals' DYSCORBAN (ifetroban), Rocket Pharmaceuticals' REN-001, Solid Biosciences' AVB-401 and SGT-601, among others. Danicamtiv (MYK-491), developed by Bristol Myers Squibb, is an orally available small molecule aimed at enhancing cardiac contractility. It works by increasing the formation of myosin-actin cross-bridges during heart muscle contraction, while maintaining diastolic function. Since myosin is the motor protein responsible for contracting the heart muscle by interacting with actin, MYK-491 targets the fundamental biomechanical dysfunction seen in patients with systolic heart failure and dilated cardiomyopathy. In these conditions, the left ventricle is too weakened and enlarged to pump blood efficiently. By boosting myosin-actin interactions, MYK-491 seeks to improve cardiac performance. BC007, developed by Berlin Cures, is a DNA aptamer that neutralizes harmful autoantibodies targeting the beta-1 adrenoceptor—a key G-protein coupled receptor involved in regulating heart rate and contractile force. Delivered intravenously, BC007 is part of the company's APTACURES platform, which focuses on aptamers that bind to autoantibodies against GPCRs. Ifetroban, the active component of DYSCORBAN from Cumberland Pharmaceuticals, is a highly selective thromboxane receptor (TPr) antagonist. It is designed to block fibrotic and inflammatory pathways in the heart, especially those initiated by the absence of dystrophin protein. By inhibiting key molecular signals involved in inflammation and tissue scarring, ifetroban may help preserve cardiac function in patients at risk of fibrotic damage. The anticipated launch of these emerging dilated cardiomyopathy drugs are poised to transform the dilated cardiomyopathy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the dilated cardiomyopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about dilated cardiomyopathy clinical trials, visit @ Dilated Cardiomyopathy Pipeline Market Dilated Cardiomyopathy Market Dynamics The dilated cardiomyopathy market dynamics are anticipated to change in the coming years. The increasing prevalence of drug or alcohol abuse, cardiac muscle infections, and rising public awareness in the 7MM are anticipated to fuel the growth of the dilated cardiomyopathy market, supported by advances in device therapies such as ICD, CRT, and surgical interventions that significantly reduce mortality and hospitalization rates; furthermore, opportunities exist to enhance genetic screening for at-risk individuals, improve disease management, and develop novel therapies with better efficacy, duration of action, safety profiles, and biomarker identification. Furthermore, many potential therapies are being investigated for the treatment of dilated cardiomyopathy, and it is safe to predict that the treatment space will significantly impact the dilated cardiomyopathy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the dilated cardiomyopathy market in the 7MM. However, several factors may impede the growth of the dilated cardiomyopathy market. Dilated cardiomyopathy is a heterogeneous condition with various underlying etiologies, clinical manifestations, and prognostic factors, making it difficult to develop standardized treatment approaches; it is challenging to diagnose due to its nonspecific symptoms and variable presentation, often leading to delays in diagnosis and treatment initiation, and despite advancements in therapy, curative options remain lacking, existing treatments primarily aim to alleviate symptoms and slow progression, while the condition is associated with a poor long-term prognosis, with survival rates below 50% at 10 years and many patients facing progressive heart failure, arrhythmias, and sudden cardiac death. Moreover, dilated cardiomyopathy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the dilated cardiomyopathy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the dilated cardiomyopathy market growth. Dilated Cardiomyopathy Report Metrics Details Study Period 2020–2034 Dilated Cardiomyopathy Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Dilated Cardiomyopathy Market Size in 2023 USD 464 Million Key Dilated Cardiomyopathy Companies Bristol-Myers Squibb, Berlin Cures, Cumberland Pharmaceutical, Rocket Pharmaceutical, Solid Bioscience, and others Key Dilated Cardiomyopathy Therapies Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), REN-001, AVB-401, SGT-601, and others Scope of the Dilated Cardiomyopathy Market Report Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and emerging therapies Dilated Cardiomyopathy Market Dynamics: Conjoint Analysis of Emerging Dilated Cardiomyopathy Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Dilated Cardiomyopathy Market Access and Reimbursement Discover more about dilated cardiomyopathy treatment drugs in development @ Dilated Cardiomyopathy Clinical Trials Table of Contents 1. Dilated Cardiomyopathy Market Key Insights 2. Dilated Cardiomyopathy Market Report Introduction 3. Dilated Cardiomyopathy Market Overview at a Glance 4. Dilated Cardiomyopathy Market Executive Summary 5. Disease Background and Overview 6. Dilated Cardiomyopathy Treatment and Management 7. Dilated Cardiomyopathy Epidemiology and Patient Population 8. Patient Journey 9. Dilated Cardiomyopathy Marketed Drugs 10. Dilated Cardiomyopathy Emerging Drugs 11. Seven Major Dilated Cardiomyopathy Market Analysis 12. Dilated Cardiomyopathy Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Dilated Cardiomyopathy Pipeline Dilated Cardiomyopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dilated cardiomyopathy companies, including Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics, among others. Dilated Cardiomyopathy Epidemiology Forecast Dilated Cardiomyopathy Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted dilated cardiomyopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Hypertrophic Cardiomyopathy Market Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertrophic cardiomyopathy companies including Bristol Myers Squibb, Cytokinetics, Novartis, Imbria Pharmaceuticals, Univar Solutions B.V., among others. Hypertrophic Cardiomyopathy Pipeline Hypertrophic Cardiomyopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertrophic cardiomyopathy companies, including Cytokinetics, Imbria, Bristol-Myers Squibb, Tenaya Therapeutics, Lexeo Therapeutics, Inc., BioMarin, among others. Restrictive Cardiomyopathy Market Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key restrictive cardiomyopathy companies including GlaxSoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
